¶ Protein Aggregation and Misfolding in Neurodegeneration
¶ Introduction
Protein Aggregation And Misfolding In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Schematic showing protein misfolding and aggregation in neurodegenerative diseases. Image: Wikimedia Commons (CC BY-SA 3.0).
¶ Overview
Protein misfolding and aggregation is the unifying pathological hallmark of virtually all [neurodegenerative diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases.
Despite the diverse clinical presentations and distinct brain regions affected in conditions such as [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, [Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX--, [amyotrophic lateral sclerosis (ALS)[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX--, [Frontotemporal Dementia (FTD)[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX--, and [prion diseases[/diseases/[prion-diseases[/diseases/[prion-diseases[/diseases/[prion-diseases--TEMP--/diseases)--FIX--, each is fundamentally driven by the conversion of specific proteins from their native, functional conformations into misfolded, aggregation-prone forms that assemble into toxic oligomers, protofibrils, and amyloid fibrils 1(https://link.springer.com/article/10.1186/s12964-024-01791-8) [1].
The field has undergone a paradigm shift in recent years.
Rather than viewing the large, insoluble protein deposits (plaques, tangles, Lewy bodies, inclusions) as the primary toxic species, evidence now strongly supports that smaller, soluble oligomeric intermediates are the most neurotoxic assemblies.
Furthermore, the discovery that these misfolded proteins can propagate through a prion-like seeding mechanism — spreading from cell to cell and templating the misfolding of normal protein — has transformed our understanding of disease progression and has opened new avenues for therapeutic intervention 2(](https://www.mdpi.com/1422-0067/26/21/10568) [2].
¶ Disease-Specific Aggregating Proteins
Each major neurodegenerative disease is associated with the aggregation of one or more characteristic proteins:
| Disease | Primary Aggregating Protein | Aggregate Type | Key Brain Regions |
|---|---|---|---|
| [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- | [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX--, [Tau[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein--TEMP--/entities)--FIX-- | [Amyloid] plaques, neurofibrillary tangles | [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX--, [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- |
| [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- | [α-synuclein/proteins/alpha | Lewy bodies, Lewy neurites | [substantia nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra--TEMP--/brain-regions)--FIX--, [brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem--TEMP--/brain-regions)--FIX-- |
| [Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX-- | [huntingtin[/proteins/[huntingtin[/proteins/[huntingtin[/proteins/[huntingtin--TEMP--/proteins)--FIX-- (mHTT)] | Intranuclear inclusions | [striatum[/brain-regions/[striatum[/brain-regions/[striatum[/brain-regions/[striatum--TEMP--/brain-regions)--FIX--, [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- |
| [ALS[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX-- / [FTD[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX-- | [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX--, [FUS[/entities/[fus[/entities/[fus[/entities/[fus--TEMP--/entities)--FIX--, [SOD1/proteins/sod1 | Cytoplasmic inclusions | Motor [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--, spinal cord, frontal/temporal [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- |
| [Prion diseases[/diseases/[prion-diseases[/diseases/[prion-diseases[/diseases/[prion-diseases--TEMP--/diseases)--FIX-- | [PrP (prion protein) | PrP^Sc amyloid | [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--, [thalamus[/brain-regions/[thalamus[/brain-regions/[thalamus[/brain-regions/[thalamus--TEMP--/brain-regions)--FIX--, [cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum--TEMP--/brain-regions)--FIX-- |
| [MSA[/diseases/[msa[/diseases/[msa[/diseases/[msa--TEMP--/diseases)--FIX--, [Lewy body dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia--TEMP--/diseases)--FIX-- | [α-synuclein/proteins/alpha | Glial cytoplasmic inclusions, Lewy bodies | [basal ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia--TEMP--/brain-regions)--FIX--, [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- |
¶ Molecular Mechanisms of Protein Misfolding
¶ Protein Folding and the Energy Landscape
Native protein folding follows a funnel-shaped energy landscape, with the correctly folded state representing the global free-energy minimum. Misfolding occurs when proteins become trapped in local energy minima that expose aggregation-prone sequences (typically hydrophobic stretches or β-sheet-forming regions). Several factors promote misfolding 1(https://link.springer.com/article/10.1186/s12964-024-01791-8):
- Genetic mutations: Disease-causing mutations (e.g., [PSEN1[/genes/[psen1[/genes/[psen1[/genes/[psen1--TEMP--/genes)--FIX--/[PSEN2[/genes/[psen2[/genes/[psen2[/genes/[psen2--TEMP--/genes)--FIX-- in Alzheimer's, [SNCA[/genes/[snca[/genes/[snca[/genes/[snca--TEMP--/genes)--FIX-- in [Parkinson]'s, [HTT[/genes/[htt[/genes/[htt[/genes/[htt--TEMP--/genes)--FIX-- polyglutamine expansion in Huntington's) destabilize native protein structure or promote aggregation-prone conformations.
- Post-translational modifications: Hyperphosphorylation (as in tau], ubiquitination, acetylation, SUMOylation, and oxidative modifications alter protein stability and aggregation propensity.
- Aging-related proteostasis decline: The capacity of the protein quality control network ([chaperones], [proteasome], autophagy) declines with age, reducing the cell's ability to refold or clear misfolded proteins 3(.
- Environmental stress: [oxidative stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX--, metal ion dysregulation, pH changes, and metabolic dysfunction promote protein misfolding [3].
¶ Nucleation-Dependent Polymerization
Amyloid fibril formation follows a nucleation-dependent polymerization mechanism with three phases:
- Lag phase (nucleation): Monomers undergo conformational change and assemble into small oligomeric nuclei. This is the rate-limiting step and is thermodynamically unfavorable, requiring the formation of a critical nucleus 2(](https://www.mdpi.com/1422-0067/26/21/10568).
- Elongation phase: Once stable nuclei form, they serve as templates for rapid monomer addition and fibril elongation. This phase is characterized by exponential growth.
- Plateau phase: Monomer depletion and fibril fragmentation reach equilibrium, establishing a steady state [4].
Secondary nucleation processes — including fibril fragmentation and surface-catalyzed nucleation (where existing fibrils catalyze the formation of new nuclei on their surface) — dramatically accelerate aggregation and are now recognized as the dominant pathway for generating toxic oligomeric species in diseases like Alzheimer's 4(](https://link.springer.com/article/10.1007/s40473-026-00320-w) [5].
¶ Amyloid Cross-β Structure
Despite vastly different primary sequences, amyloid fibrils from diverse proteins share a common cross-β structural motif: β-strands oriented perpendicular to the fibril axis, with hydrogen bonds running parallel to it.
This structure is remarkably stable and resistant to proteolytic degradation, detergent solubilization, and thermal denaturation.
Cryo-electron microscopy has revealed disease-specific polymorphic fibril structures ("strains") for [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX--, tau, and α-synuclein/proteins/alpha, with different structures correlating with distinct clinical phenotypes 2( [6].
¶ Toxic Species: The Oligomer Hypothesis
¶ Oligomers vs. Fibrils
A fundamental shift in the field has been the recognition that soluble oligomeric intermediates, rather than mature amyloid fibrils or plaques, are the primary mediators of neurotoxicity:
- [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- oligomers]: Soluble [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- oligomers (dimers, trimers, dodecamers) correlate more strongly with cognitive decline in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- than plaque burden. Oligomers disrupt synaptic function, impair [long-term potentiation ([LTP[/entities/[long-term-potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation--TEMP--/entities)--FIX--, and trigger tau hyperphosphorylation 5(https://www.mdpi.com/1873-149X/33/1/14).
- α-Synuclein oligomers: Prefibrillar α-synuclein oligomers permeabilize membranes, disrupt mitochondrial function, and are more toxic than mature Lewy body fibrils.
- Tau oligomers: Soluble tau oligomers impair [axonal transport[/mechanisms/[axonal-transport-defects[/mechanisms/[axonal-transport-defects[/mechanisms/[axonal-transport-defects--TEMP--/mechanisms)--FIX--, disrupt microtubule dynamics, and seed tau aggregation in healthy [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- 6(https://pmc.ncbi.nlm.nih.gov/articles/PMC11302116/) [7].
¶ Mechanisms of Oligomer Toxicity
Oligomeric species exert toxicity through multiple pathways:
- Membrane disruption: Oligomers insert into or form pores in lipid bilayer membranes, disrupting ion homeostasis and membrane integrity.
- Receptor binding: Oligomers interact with cell-surface receptors including [NMDA receptor[/entities/[nmda-receptor[/entities/[nmda-receptor[/entities/[nmda-receptor--TEMP--/entities)--FIX-- receptors], PrP^C, mGluR5, and insulin receptors, triggering aberrant signaling cascades 5(https://www.mdpi.com/1873-149X/33/1/14).
- Calcium dysregulation: Membrane pore formation and receptor-mediated signaling cause pathological [calcium] influx.
- [Mitochondrial dysfunction[/mechanisms/[mitochondrial-dysfunction[/mechanisms/[mitochondrial-dysfunction[/mechanisms/[mitochondrial-dysfunction--TEMP--/mechanisms)--FIX--: Oligomers are imported into mitochondria, disrupting electron transport chain function and promoting [reactive oxygen species ([ROS[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- generation.
- Synaptic toxicity: Oligomeric species disrupt synaptic vesicle release, receptor trafficking, and [dendritic spine] morphology, leading to [synaptic dysfunction[/mechanisms/[synaptic-dysfunction[/mechanisms/[synaptic-dysfunction[/mechanisms/[synaptic-dysfunction--TEMP--/mechanisms)--FIX-- and loss [8].
¶ Prion-Like Propagation
¶ Seeding and Templated Misfolding
A transformative discovery in neurodegenerative disease research has been that misfolded proteins can self-propagate through a [prion-like] seeding mechanism. In this process, misfolded protein "seeds" interact with normally folded copies of the same protein and template their conversion to the misfolded state, analogous to the mechanism of [prion diseases[/diseases/[prion-diseases[/diseases/[prion-diseases[/diseases/[prion-diseases--TEMP--/diseases)--FIX-- 2(https://www.mdpi.com/1422-0067/26/21/10568) [9].
This has been demonstrated for:
- Tau propagation]: Injection of tau fibrils into mouse brain induces spreading tauopathy that follows anatomical connectivity patterns, recapitulating Braak staging in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--.
- [α-synuclein/proteins/alpha propagation: Injection of α-synuclein preformed fibrils (PFFs) triggers Lewy-like pathology spreading throughout the brain. The Braak hypothesis of [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- posits that α originates in the [gut] or olfactory bulb and ascends via neuronal connections.
- [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- propagation: [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- aggregates can seed pathology in cell culture and animal models, potentially explaining the anatomical spread of pathology in ALS/FTD.
- [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- seeding]: [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- aggregates can seed [amyloid] deposition when transmitted to transgenic mice [10].
¶ Cell-to-Cell Spreading Mechanisms
Misfolded proteins spread between cells through several mechanisms:
- Exosome-mediated release: Aggregated proteins are packaged into [exosomes[/entities/[exosomes[/entities/[exosomes[/entities/[exosomes--TEMP--/entities)--FIX-- and released into the extracellular space, where they are taken up by neighboring cells.
- Direct membrane penetration: Some oligomeric species can directly penetrate cell membranes.
- Tunneling nanotubes: Thin membrane projections connecting adjacent cells allow direct transfer of aggregates between cytoplasms.
- Synaptic transmission: Trans-synaptic spread of aggregated proteins (particularly tau and α along neural circuits explains the stereotypical anatomical progression patterns observed clinically.
- [Glymphatic] clearance failure: Impaired glymphatic drainage may contribute to the accumulation and spread of aggregated proteins in the extracellular space 7(https://pmc.ncbi.nlm.nih.gov/articles/PMC12574514/) [11].
¶ Cross-Seeding
A phenomenon of growing interest is cross-seeding, where misfolded aggregates of one protein can template and accelerate the aggregation of a different protein. This has been demonstrated for:
- α-Synuclein and tau: These proteins can interact and cross-seed each other, potentially explaining the frequent co-occurrence of synucleinopathy and tauopathy in aging brains.
- [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- and tau: [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- oligomers promote tau phosphorylation and aggregation, linking the two cardinal pathologies of [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--.
- [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- and α-synuclein: Interaction between these proteins may explain the Lewy body pathology seen in many Alzheimer's patients 2(https://www.mdpi.com/1422-0067/26/21/10568) [12].
¶ Protein Quality Control and Clearance
¶ Molecular Chaperones
[Heat shock proteins (HSPs)[/entities/[heat-shock-proteins[/entities/[heat-shock-proteins[/entities/[heat-shock-proteins--TEMP--/entities)--FIX-- and other molecular chaperones represent the first line of defense against protein misfolding:
- HSP70/HSC70: Bind exposed hydrophobic regions of misfolded proteins, promoting refolding or targeting irreversibly misfolded proteins for degradation.
- HSP90: Stabilizes client proteins and prevents aggregation. Inhibition of HSP90 can paradoxically induce a heat shock response that upregulates protective chaperones.
- Small HSPs (HSP27, αB-crystallin): Hold partially unfolded proteins in a refolding-competent state, preventing irreversible aggregation.
- Chaperone capacity decline: Aging is associated with decreased chaperone expression and function, reducing the cellular capacity to prevent aggregation 1(https://link.springer.com/article/10.1186/s12964-024-01791-8).
¶ Ubiquitin-Proteasome System
The [ubiquitin-proteasome system ([UPS] degrades soluble misfolded proteins through polyubiquitination and proteasomal proteolysis. In neurodegenerative diseases, the [UPS] is overwhelmed by aggregated proteins:
- Large amyloid fibrils cannot enter the narrow proteasome barrel and may actually inhibit proteasome function.
- Ubiquitinated inclusions are a hallmark of most neurodegenerative diseases, indicating failed proteasomal degradation.
- [UPS] impairment creates a feed-forward loop, as accumulating misfolded proteins further inhibit proteasome activity 1(https://link.springer.com/article/10.1186/s12964-024-01791-8).
¶ Autophagy-Lysosomal Pathway
[autophagy[/entities/[autophagy[/entities/[autophagy[/entities/[autophagy--TEMP--/entities)--FIX--, particularly macroautophagy and chaperone-mediated autophagy (CMA), is critical for clearing aggregated proteins that are too large for proteasomal degradation:
- Macroautophagy: Sequesters aggregated proteins in autophagosomes for delivery to lysosomes. Regulated by [mTOR[/mechanisms/[mtor-neurodegeneration[/mechanisms/[mtor-neurodegeneration[/mechanisms/[mtor-neurodegeneration--TEMP--/mechanisms)--FIX-- and [TFEB[/entities/[tfeb[/entities/[tfeb[/entities/[tfeb--TEMP--/entities)--FIX--.
- Aggrephagy: Selective autophagy of protein aggregates mediated by receptors such as p62/SQSTM1 and NBR1.
- Chaperone-mediated autophagy: Direct translocation of substrate proteins across the lysosomal membrane via LAMP-2A.
- [Lysosomal dysfunction[/mechanisms/[lysosomal-dysfunction[/mechanisms/[lysosomal-dysfunction[/mechanisms/[lysosomal-dysfunction--TEMP--/mechanisms)--FIX--: Lysosomal enzymes may be insufficient to fully degrade amyloid fibrils, leading to incomplete clearance and lysosomal storage 8(https://pmc.ncbi.nlm.nih.gov/articles/PMC12630200/).
¶ Unfolded Protein Response
The [unfolded protein response ([UPR[/mechanisms/[endoplasmic-reticulum-stress[/mechanisms/[endoplasmic-reticulum-stress[/mechanisms/[endoplasmic-reticulum-stress--TEMP--/mechanisms)--FIX-- in the endoplasmic reticulum senses and responds to the accumulation of misfolded proteins. Chronic [UPR[/mechanisms/[endoplasmic-reticulum-stress[/mechanisms/[endoplasmic-reticulum-stress[/mechanisms/[endoplasmic-reticulum-stress--TEMP--/mechanisms)--FIX-- activation in neurodegenerative diseases leads to translational repression (via PERK-eIF2α signaling), which paradoxically impairs the synthesis of synaptic proteins needed for neuronal function and survival 3(https://pmc.ncbi.nlm.nih.gov/articles/PMC12715484/).
¶ Therapeutic Strategies
¶ Preventing Aggregation
- **β-Secretase ([BACE1[/entities/[bace1[/entities/[bace1[/entities/[bace1--TEMP--/entities)--FIX--/entities/bace1.
- Antisense oligonucleotides ([ASOs[/treatments/[antisense-oligonucleotide-therapy[/treatments/[antisense-oligonucleotide-therapy[/treatments/[antisense-oligonucleotide-therapy--TEMP--/treatments)--FIX--): Reduce expression of aggregation-prone proteins (e.g., [tofersen[/treatments/[tofersen[/treatments/[tofersen[/treatments/[tofersen--TEMP--/treatments)--FIX-- for SOD1-ALS, [nusinersen[/treatments/[nusinersen[/treatments/[nusinersen[/treatments/[nusinersen--TEMP--/treatments)--FIX-- for SMA).
¶ Clearing Aggregates
- [Anti-amyloid immunotherapy]: Monoclonal antibodies targeting [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- ([lecanemab[/treatments/[lecanemab[/treatments/[lecanemab[/treatments/[lecanemab--TEMP--/treatments)--FIX--, [donanemab[/treatments/[donanemab[/treatments/[donanemab[/treatments/[donanemab--TEMP--/treatments)--FIX--, [aducanumab[/treatments/[aducanumab[/treatments/[aducanumab[/treatments/[aducanumab--TEMP--/treatments)--FIX-- promote microglial phagocytosis of amyloid plaques. [lecanemab[/treatments/[lecanemab[/treatments/[lecanemab[/treatments/lecanemab--TEMP--/treatments)--FIX-- and donanemab have demonstrated statistically significant slowing of cognitive decline in Phase 3 trials 9(.
- Anti-tau immunotherapy: Antibodies targeting various tau epitopes are in clinical development, with several trials yielding disappointing results to date.
- [autophagy[/entities/[autophagy[/entities/[autophagy[/entities/[autophagy--TEMP--/entities)--FIX-- enhancers: Rapamycin ([mTOR[/mechanisms/[mtor-neurodegeneration[/mechanisms/[mtor-neurodegeneration[/mechanisms/[mtor-neurodegeneration--TEMP--/mechanisms)--FIX-- inhibitor), trehalose, and other autophagy inducers show promise in preclinical models by enhancing aggregate clearance.
¶ Enhancing Proteostasis
- HSP inducers: Arimoclomol and other compounds that enhance the heat shock response, boosting chaperone capacity.
- Proteasome activators: Enhancing [UPS] activity to improve clearance of soluble misfolded proteins.
- [UPR[/mechanisms/[endoplasmic-reticulum-stress[/mechanisms/[endoplasmic-reticulum-stress[/mechanisms/[endoplasmic-reticulum-stress--TEMP--/mechanisms)--FIX-- modulators: ISRIB and related compounds that prevent chronic [UPR[/mechanisms/[endoplasmic-reticulum-stress[/mechanisms/[endoplasmic-reticulum-stress[/mechanisms/[endoplasmic-reticulum-stress--TEMP--/mechanisms)--FIX---mediated translational repression 1(https://link.springer.com/article/10.1186/s12964-024-01791-8).
¶ Targeting Prion-Like Propagation
- Anti-seeding compounds: Small molecules that prevent seed-templated misfolding.
- Immunotherapy targeting spread: Antibodies that capture extracellular aggregated proteins before they can seed new pathology in recipient cells 9(https://link.springer.com/article/10.1186/s13195-025-01775-x).
- Exosome inhibitors: Blocking exosome-mediated release of misfolded proteins to prevent cell-to-cell spread.
¶ See Also
- [Neurodegenerative Diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases
¶ Background
The study of Protein Aggregation And Misfolding In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
¶ External Links
- PubMed - Biomedical literature
- Alzheimer's Disease Neuroimaging Initiative - Research data
- Allen Brain Atlas - Brain gene expression data
¶ Unresolved Questions: Phase Separation vs Classical Nucleation
A central unresolved issue is whether pathogenic protein aggregation is primarily initiated through classical nucleation/polymerization or whether liquid-liquid phase separation (LLPS) creates condensate states that bias proteins toward amyloid conversion. Current evidence supports a hybrid model with context-dependent dominance:
- Tau: LLPS can accelerate liquid-to-solid transitions, but secondary nucleation and chaperone interactions strongly modulate which condensates mature into toxic fibrils[13][16].
- [alpha-synuclein[/mechanisms/[alpha-synuclein[/mechanisms/[alpha-synuclein[/mechanisms/[alpha-synuclein--TEMP--/mechanisms)--FIX--: condensate aging appears to enrich beta-sheet-prone interaction motifs, linking phase behavior to nucleation kinetics rather than replacing nucleation theory[14].
- Model discrimination challenge: structural trajectory data indicate conformational transitions during LLPS, but these do not by themselves establish that LLPS is universally upstream of disease-driving amyloid nucleation[15].
- Working controversy: whether to target condensate formation directly, target nucleation/elongation chemistry, or combine both in stage-specific regimens.
¶ Unresolved Questions: Phase Separation vs Classical Nucleation
A central unresolved issue is whether pathogenic protein aggregation is primarily initiated through classical nucleation/polymerization or whether liquid-liquid phase separation (LLPS) creates condensate states that bias proteins toward amyloid conversion. Current evidence supports a hybrid model with context-dependent dominance:
- Tau: LLPS can accelerate liquid-to-solid transitions, but secondary nucleation and chaperone interactions strongly modulate which condensates mature into toxic fibrils[13][16].
- Alpha-synuclein: condensate aging appears to enrich beta-sheet-prone interaction motifs, linking phase behavior to nucleation kinetics rather than replacing nucleation theory[14].
- Model discrimination challenge: structural trajectory data indicate conformational transitions during LLPS, but these do not by themselves establish that LLPS is universally upstream of disease-driving amyloid nucleation[15].
- Working controversy: whether to target condensate formation directly, target nucleation/elongation chemistry, or combine both in stage-specific regimens.
¶ References
- [Zhang H, Bhatt DL, et al. Misfolding and aggregation in neurodegenerative diseases: protein quality control machinery as potential therapeutic clearance pathways. Cell Commun Signal. 2024;22:421. [doi:10.1186/s12964-024-01791-8. Available from:)
- [Fernandez-Ramirez MDC, et al. Current Understanding of Protein Aggregation in Neurodegenerative Diseases. Int J Mol Sci. 2025;26(21]:10568. [doi:10.3390/ijms262110568. Available from:)
- [Kamel MA, et al. Protein Misfolding in the Pathogenesis and Diagnosis of Neurodegenerative Diseases (Review]. Mol Med Rep. 2025;32(2):1-15. [doi:10.3892/mmr.2025.13525. Available from:)
- [Kumar A, et al. The Role of Protein Aggregation in Neurodegenerative Diseases: Molecular Mechanisms and Therapeutic Targets. Curr Behav Neurosci Rep. 2026;13:320. doi:10.1007/s40473-026-00320-w. Available from:)
- [Sanchez-Lopez F, et al. Amyloid-Beta Oligomers as Early Triggers of Neuronal Cytoskeleton Dysfunction in Alzheimer's Disease. NeuroSci. 2025;33(1]:14. [doi:10.3390/neurosci33010014. Available from:)
- [Zhang Y, et al. Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies. Transl Neurodegener. 2024;13:40. [doi:10.1186/s40035-024-00429-6. Available from:)
- [Keshri PK, et al. Protein aggregation in neurodegenerative diseases. Ageing Res Rev. 2025;105:102718. [doi:10.1016/j.arr.2025.102718. Available from:)
- [Poewe W, et al. Protein misfolding: understanding biology to classify and treat synucleinopathies. Nat Rev Neurol. 2025;21:723-738. [doi:10.1038/s41582-025-01072-3. Available from:)
- [Congdon EE, et al. Revisiting the therapeutic landscape of tauopathies: assessing the current pipeline and clinical trials. Alzheimers Res Ther. 2025;17:75. doi:10.1186/s13195-025-01775-x. Available from:)
- Soto C, Pritzkow S. Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. Nat Neurosci. 2018;21(10]:1332-1340. DOI:10.1038/s41593-018-0235-9
- Chiti F, Dobson CM. Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress over the Last Decade. Annu Rev Biochem. 2017;86:27-68. DOI:10.1146/annurev-biochem-061516-045115
- Jucker M, Walker LC. Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. Nat Neurosci. 2018;21(10]:1341-1349. DOI:10.1038/s41593-018-0238-6
- Rai et al., Chaperone-mediated heterotypic phase separation regulates liquid-to-solid phase transitions of tau into amyloid fibrils (2025)
- Tang et al., Determinants of alpha-synuclein phase separation and condensate aging (2025)
- Olivieri et al., Direct observation of tau conformational transitions and phase behavior (2025)
- Morman et al., Chaperone-mediated regulation of tau phase separation, fibrillation, and toxicity (2025)
¶ Related Signaling Pathways
- GDNF Signaling Pathway in Neurodegeneration — Neurotrophic factor signaling and protein clearance
- WNT/β-Catenin Signaling Pathway — WNT signaling dysregulation in protein aggregation
- S1P Signaling in Neurodegeneration — Sphingosine-1-phosphate signaling and proteostasis
¶ Confidence Assessment
🟡 Moderate Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 16 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 33% |
| Mechanistic Completeness | 75% |
Overall Confidence: 51%